INO
Inovio Pharmaceuticals, Inc.2.3200
+0.0600+2.65%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms, adds launch/GBM nuggets
Q&A largely reaffirmed prepared remarks on INO-3107's BLA, with management confirming no new clinical data needed ahead of FDA accelerated approval talks—just the submitted assessment aid. They highlighted commercial partners' learnings from PAPZIMEOS rollout, emphasizing 3107's simpler logistics without ultra-cold chain or treatment-window surgeries. GBM trial details surfaced CTLA-4/PD-1 synergy boosting prior T-cell data, targeting unmethylated patients. No surprises. Post-approval, INO-3112 Phase III with Coherus hinges on cash post-3107. Investors watch FDA meeting and launch speed.
Key Stats
Market Cap
159.39MP/E (TTM)
-Basic EPS (TTM)
-2.72Dividend Yield
0%Recent Filings
8-K
BLA submitted for INO-3107
Inovio completed its rolling BLA submission for INO-3107 in RRP adults on November 10, 2025, seeking accelerated approval and priority review, with file acceptance expected by year-end and potential mid-2026 launch if granted. Operating expenses dropped to $21.2M from $27.3M year-over-year, yet net loss widened to $45.5M on $22.5M warrant liability hit. Cash funds operations into Q2 2026.
10-Q
Q3 FY2025 results
Inovio narrowed its Q3 operating loss to $21.2M from $27.3M y/y (derived), driven by 29% lower R&D spend as INO-3107 costs fell 52% post-trial completion. Net loss widened to $45.5M ($0.87/share) from $25.2M ($0.89/share) y/y, with the delta mainly from $22.5M unfavorable change in fair value of common stock warrant liabilities now at $50.4M. Cash and short-term investments stood at $50.8M, funding operations into Q2 2026; July's $22.4M offering propped liquidity while turning stockholders' equity negative. BLA for INO-3107 completed November 2025. Cash burn persists.
10-Q
Q2 FY2025 results
Inovio Pharmaceuticals narrowed its Q2 net loss to $23.5M from $32.2M y/y, with operating expenses dropping 31% to $23.1M on lower R&D for INO-3107 and other programs, while revenue stayed flat at nil. YTD net loss improved to $43.2M from $62.7M, driven by 30% lower operating costs and a $1.8M gain from warrant liability fair value changes, though EPS widened to $(1.12) from $(2.48) on higher shares outstanding (38.7M vs 25.2M). Cash burn eased to $47.7M YTD from $57.0M, leaving $47.5M in cash and equivalents at quarter-end, bolstered by $22.5M from a July offering extending runway into Q2 2026. No free cash flow disclosed in the 10-Q. Litigation with GeneOne settled in August, clearing a key overhang. Yet competition in DNA medicines intensifies.
8-K
Inovio cuts losses, advances BLA
Inovio Pharmaceuticals reported Q2 2025 net loss of $23.5 million, down from $32.2 million last year, as R&D expenses dropped to $14.5 million from $23.1 million amid focused spending on INO-3107. The company completed device testing and requested rolling BLA submission for INO-3107 in 2H25, targeting FDA acceptance by year-end and potential 2026 launch for RRP treatment. Cash stood at $47.5 million, bolstered by $22.5 million from a July stock offering, funding operations into Q2 2026. Long-term data showed sustained surgery reductions for RRP patients.
8-K
Inovio prices $25M offering
Inovio Pharmaceuticals inked an underwriting deal on July 2, 2025, to sell 14,285,715 shares of common stock plus Series A and B warrants at $1.75 each, targeting $25 million in gross proceeds. Net proceeds should hit $22.5 million after fees, with closing eyed for July 7, assuming no hiccups. Series A warrants expire in 12 months or 30 days post-FDA BLA acceptance for INO-3107; Series B last five years. Yet market volatility could derail the close.
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
GOVX
GeoVax Labs, Inc.
0.29-0.05
INAB
IN8bio, Inc.
1.50-0.10
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
INVA
Innoviva, Inc.
19.92-0.22
MRNA
Moderna, Inc.
29.89-0.03
NNVC
NanoViricides, Inc.
1.29+0.06
NVAX
Novavax, Inc.
6.54-0.04
REGN
Regeneron Pharmaceuticals, Inc.
746.36-6.26
VIR
Vir Biotechnology, Inc.
6.48-0.24